<DOC>
	<DOCNO>NCT00203411</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness bevacizumab capecitabine combination frail patient untreated metastatic colorectal cancer .</brief_summary>
	<brief_title>Bevacizumab Plus Capecitabine ( Xeloda ) Patients With Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study evaluate tolerability , safety , feasibility combination bevacizumab capecitabine small number frail patient metastatic colorectal cancer compromise performance status . Preclinical study suggest combination chemotherapy anti-angiogenic therapy offer increase anti-tumor effect compare either treatment alone .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically cytologically proven adenocarcinoma colon first diagnosis Stage IV disease , least one measurable lesion accord RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 2 No prior chemotherapy metastatic colorectal cancer Prior adjuvant chemotherapy permit . At least 28 day since prior surgery If female childbearing potential , pregnancy test negative willing use effective contraception treatment least 3 month thereafter . Required laboratory value : Absolute neutrophil count &gt; 1.5 x 10^9/L Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 100 x 10^9/L Creatinine &lt; 2.0 mg/dL Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) ( Patients document Gilbert 's syndrome eligible . ) Alkaline phosphatase AST/ALT within follow parameter . In determine eligibility , abnormal two value ( AST ALT ) use : Alkaline phosphate AST/ALT &lt; = ULN Alkaline phosphate &gt; 1x &lt; = 2.5x AST/ALT &lt; = ULN Alkaline phosphate &gt; 2.5x &lt; = 5x AST/ALT &lt; = ULN Alkaline phosphate &lt; = ULN AST/ALT &gt; 1x &lt; = 1.5x Alkaline phosphate &gt; 1x &lt; = 2.5 x AST/ALT &gt; 1x &lt; = 1.5x Alkaline phosphate &lt; = ULN AST/ALT &gt; 1x &lt; = 2.5x Prior chemotherapy metastatic colorectal cancer Prior treatment antiangiogenic agent Concurrent therapy nonprotocol anticancer therapy Current prior history central nervous system brain metastasis Presence neuropathy &gt; grade 2 ( NCICommon Toxicity Criteria ( CTC ) version 3.0 ) baseline Presence nonhealing wound , fracture , ulcer , presence clinically significant ( &gt; grade 2 ) peripheral vascular disease History malignancy within past 5 year , exception nonmelanoma skin cancer carcinomainsitu cervix Clinically significant cardiovascular disease ( e.g. , blood pressure [ BP ] &gt; 150/100 , myocardial infarction stroke within past 6 month , unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication Active peptic ulcer disease , inflammatory bowel disease , gastrointestinal condition increase risk perforation ; history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin therapy Active infection require parenteral antimicrobial The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication Inability comply study protocol followup procedure Pregnancy lactation A history severe hypersensitivity reaction bevacizumab , capecitabine drug formulate polysorbate 80 . Evidence bleed diathesis coagulopathy . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study Unstable angina Urine protein creatinine ratio great equal 1 . Therapeutic anticoagulation oral anticoagulation medication , specifically coumarins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>